Retrospective benefit following individualized naturopathic therapy in HIV-patients at different stages. Author: Wolfstadter HD; Sacher J; Hopfenmuller W; Stange R Address: Universitatsklinikum Steglitz, Freien Universitat Berlin. Source: Int Conf AIDS, 1992 Jul 19-24, 8:3, 147 (abstract no. PuB 7588) Abstract: OBJECTIVE: To assess the long-term efficacy and benefit of a complementary treatment regimen, we investigated on laboratory findings and clinical outcome in a cohort of 175 out-patients (CDC II-IV E) successively treated since 1986. METHODS AND PATIENTS: The therapeutic regimen comprised autologous ozone transfusions, homeopathy, phytotherapy, therapy with enzymes, mineral-, vitamin- and trace element substitution, nutritional management, correction of intestinal dysbacteria and psychophysical means, set up on an individualized basis. No conventional antiviral therapy was given. Patients (all male homosexuals) were divided into 5 groups (Gr. I- V) according to their CD4 lymphocyte counts at entry into therapy (Gr.I n = 22, CD4 0-50; Gr. II n = 12, CD4 51-100; Gr. III n = 17, CD4 101-200; Gr. IV n = 81, CD4 201-500; Gr. V n = 53, CD4 greater than 500 [/microliters]) and 15 hematological and biochemical parameters were evaluated with individual regression analysis according to the length of observation of patients (min. obs.time in Gr. I-III 3 months, min. obs.time in Gr. IV and V 6 months). Moreover we studied the incidence and severity of opportunistic infections and overall QOL during the observed period. RESULTS: Patients in Gr. I presented a median loss of CD4 lymphocytes per month of 0.54 cells/microliters(range -42.0 to 4.50, median obs.time 8 months), Gr. II median loss 3.65 cells/microliters (range -5.9 to 8.8, median obs.time 10.5 mo.), Gr. III median loss 4.98 cells/microliters (range -13.5 to 11.0, median obs.time 16.8 mo.). In Gr. V, apparently due to the earlier stage of disease, no clear statistical trend of helper-cell deterioration could be observed. Patients in Gr. IV, with an approved indication for antiviral therapy, presented a median loss of CD4-cells of 4.47/microliters (range -17.2 to 37.5, median obs.time was 25.4 mo.). Compared to CD4 lymphocyte deterioration given in the literature for patients under antiviral therapy, 52% of our patients in Gr. IV exceeded these values, while 24.6% remained below. No substantial adverse events or side effects accompanied the therapies, thus we found QOL generally increased. CONCLUSIONS: Our results suggest that patient performance under a combined and individualized naturopathic regimen might be to some extend improved with respect to data collected from cohorts in the literature. Further investigation including controlled clinical trials on different aspects of the single therapies is necessary.